Skip to search formSkip to main contentSkip to account menu

RAP-536

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Recombinant Fusion Proteins

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Effect of Rap-536 on MDS PDX-Murine Models with or without SF3B1 Mutation
Introduction: Anemia is the most frequent cytopenia in myelodysplastic syndromes (MDS) and patients will require red blood cell… 
2015
2015
Rap-536 (Murine ACE-536/Luspatercept) Inhibits Smad2/3 Signaling and Promotes Erythroid Differentiation By Restoring GATA-1 Function in Murine b-Thalassemia
We have previously reported that Smad2/3 signaling (of the TGFβ superfamily) is elevated in myelodysplastic syndromes (MDS) and… 
2013
2013
Modified Activin Receptor Type IIb-Fc Fusion Protein (RAP-536) Decreases Anemia In a Murine Model Of Myelodysplastic Syndrome and Improves Overall Survival
Myelodysplastic syndromes (MDS) are caused due to abnormal proliferation and differentiation of pluripotent hematopoietic stem… 
2010
2010
RAP-536, A Soluble Activin Receptor Type IIb Murine IgG-Fc Fusion Protein, Prevents Myelodysplastic Syndrome Related Anemia
Abstract 978 Myelodysplastic syndrome (MDS) is a premalignant disease characterized by ineffective hematopoiesis. MDS patients… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)